Product Description:

• SKYRIZI is an interleukin-23 antagonist indicated for the treatment of:
• moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
• active psoriatic arthritis in adults.
• moderately to severely active Crohn's disease in adults.

How to use:

• Plaque Psoriasis and Psoriatic Arthritis:
• 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
• Crohn’s Disease:
• Obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI.
• The recommended induction dosage is 600 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage to maintain therapeutic response.

Caution & Warnings:

• Hypersensitivity Reactions
• SKYRIZI may increase the risk of infection.
• Evaluate for TB prior to initiating treatment with SKYRIZI.
• Evaluate for TB prior to initiating treatment with SKYRIZI.
• Avoid use of live vaccines.

Side Effects:

• Upper respiratory infections
• Headache
• Fatigue
• Injection site reactions
• Tinea infections.

Ingredients:

• Risankizumab-rzaa 150mg.